» Articles » PMID: 34572799

Immune Checkpoints in Cancers: From Signaling to the Clinic

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Sep 28
PMID 34572799
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

The immune system is known to help fight cancers. Ten years ago, the first immune checkpoint inhibitor targeting CTLA4 was approved by the FDA to treat patients with metastatic melanoma. Since then, immune checkpoint therapies have revolutionized the field of oncology and the treatment of cancer patients. Numerous immune checkpoint inhibitors have been developed and tested, alone or in combination with other treatments, in melanoma and other cancers, with overall clear benefits to patient outcomes. However, many patients fail to respond or develop resistance to these treatments. It is therefore essential to decipher the mechanisms of action of immune checkpoints and to understand how immune cells are affected by signaling to be able to understand and overcome resistance. In this review, we discuss the signaling and effects of each immune checkpoint on different immune cells and their biological and clinical relevance. Restoring the functionality of T cells and their coordination with other immune cells is necessary to overcome resistance and help design new clinical immunotherapy strategies. In this respect, NK cells have recently been implicated in the resistance to anti-PD1 evoked by a protein secreted by melanoma, ITGBL1. The complexity of this network will have to be considered to improve the efficiency of future immunotherapies and may lead to the discovery of new immune checkpoints.

Citing Articles

Toxicity of Cancer Immunotherapies in Older Patients: Does Age Make a Difference?.

Cil E, Gomes F Drugs Aging. 2024; 41(10):787-794.

PMID: 39368044 DOI: 10.1007/s40266-024-01149-2.


Identification of novel disulfidptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of skin cutaneous melanoma patients.

Cheng S, Wang X, Yang S, Liang J, Song C, Zhu Q Skin Res Technol. 2024; 30(7):e13814.

PMID: 38924611 PMC: 11197043. DOI: 10.1111/srt.13814.


Animal model considerations for chordoma research: reproducing the tumor microenvironment with humanized mice.

Campilan B, Schroeder C, Sagaityte E, Arditi J, Leary O, Ziya L Gokaslan Front Oncol. 2024; 14:1330254.

PMID: 38544830 PMC: 10965562. DOI: 10.3389/fonc.2024.1330254.


Biologics, Immunotherapies, and Cytotoxic Chemotherapy for Hepatocellular Carcinoma following Current Recommendations by the BCLC: A Review of Agents.

Gurtatta R, Whalen S, Ray Jr C Semin Intervent Radiol. 2024; 41(1):84-91.

PMID: 38495256 PMC: 10940041. DOI: 10.1055/s-0043-1778660.


Complement factor H: a novel innate immune checkpoint in cancer immunotherapy.

Saxena R, Gottlin E, Campa M, Bushey R, Guo J, Patz Jr E Front Cell Dev Biol. 2024; 12:1302490.

PMID: 38389705 PMC: 10883309. DOI: 10.3389/fcell.2024.1302490.


References
1.
Bright R, Coventry B, Eardley-Harris N, Briggs N . Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years' Experience: A Meta-Analysis of 3312 Patients. J Immunother. 2016; 40(1):21-30. DOI: 10.1097/CJI.0000000000000149. View

2.
Chaudhry A, Samstein R, Treuting P, Liang Y, Pils M, Heinrich J . Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011; 34(4):566-78. PMC: 3088485. DOI: 10.1016/j.immuni.2011.03.018. View

3.
Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher I, Sander C . Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010; 207(10):2175-86. PMC: 2947081. DOI: 10.1084/jem.20100637. View

4.
Jansson A, Barnes E, Klenerman P, Harlen M, Sorensen P, Davis S . A theoretical framework for quantitative analysis of the molecular basis of costimulation. J Immunol. 2005; 175(3):1575-85. DOI: 10.4049/jimmunol.175.3.1575. View

5.
Chen Y, Wen R, Yang S, Schuman J, Zhang E, Yi T . Identification of Shp-2 as a Stat5A phosphatase. J Biol Chem. 2003; 278(19):16520-7. DOI: 10.1074/jbc.M210572200. View